GLP1 receptor agonism ameliorates Parkinson’s disease through modulation of neuronal insulin signalling and glial suppression
Dilan Athauda,James R Evans,Laura Mahoney-Sanchez,Gurvir S Virdi,Patricia Lopez-Garcia,Anna Wernick,Aaron Wagen,Karishma D’Sa,Joanne Lachica,Stephanie Strohbuecker,Giulia Vecchi,Craig Leighton,Rebecca S. Saleeb,Judi O’Shaughnessy,Christina E. Toomey,Nirosen Vijiaratnam,Christine Girges,Yazhou Li,Maja Mustapic,Khalida Ismail,Melanie Davies,Dimitrios Kapogiannis,Minee L Choi,Mina Ryten,Mathew H. Horrocks,Nigel Greig,Thomas Foltynie,Sonia Gandhi
DOI: https://doi.org/10.1101/2024.02.28.582460
2024-02-28
Abstract:Neuronal insulin resistance is linked to the pathogenesis of Parkinson’s disease through unclear, but potentially targetable, mechanisms. We delineated neuronal and glial mechanisms of insulin resistance and glucagon-like 1 peptide (GLP-1) receptor agonism in human iPSC models of synucleinopathy, and corroborated our findings in patient samples from a Phase 2 trial of a GLP-1R agonist in Parkinson’s ( ). Human iPSC models of synucleinopathy exhibit neuronal insulin resistance and dysfunctional insulin signalling, which is associated with inhibition of the neuroprotective Akt pathways, and increased expression of the MAPK-associated p38 and JNK stress pathways. Ultimately, this imbalance is associated with cellular stress, impaired proteostasis, accumulation of α-synuclein, and neuronal loss. The GLP-1R agonist exenatide led to restoration of insulin signalling, associated with restoration of Akt signalling and suppression of the MAPK pathways in neurons. GLP-1R agonism reverses the neuronal toxicity associated with the synucleinopathy, through reduction of oxidative stress, improved mitochondrial and lysosomal function, reduced aggregation of α-synuclein, and enhanced neuronal viability. GLP-1R agonism further suppresses synuclein induced inflammatory states in glia, leading to neuroprotection through non cell autonomous effects. In the exenatide-PD2 clinical trial, exenatide treatment was associated with clinical improvement in individuals with higher baseline MAPK expression (and thus insulin resistance). Exenatide treatment led to a reduction of α-synuclein aggregates, and a reduction in inflammatory cytokine IL-6. Taken together, our patient platform defines the mechanisms of GLP-1R action in neurons and astrocytes, identifies the population likely to benefit from GLP-1R agonism, and highlights the utility of GLP-1R agonism as a disease modifying strategy in synucleinopathies.
Neuroscience